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Abstract: Introduction: We describe the clinical features and inpatient trajectories of older adults
hospitalized with COVID-19 and explore relationships with frailty. Methods: This retrospective
observational study included older adults admitted as an emergency to a University Hospital who
were diagnosed with COVID-19. Patient characteristics and hospital outcomes, primarily inpatient
death or death within 14 days of discharge, were described for the whole cohort and by frailty status.
Associations with mortality were further evaluated using Cox Proportional Hazards Regression
(Hazard Ratio (HR), 95% Confidence Interval). Results: 214 patients (94 women) were included of
whom 142 (66.4%) were frail with a median Clinical Frailty Scale (CFS) score of 6. Frail compared to
nonfrail patients were more likely to present with atypical symptoms including new or worsening
confusion (45.1% vs. 20.8%, p < 0.001) and were more likely to die (66% vs. 16%, p = 0.001). Older age,
being male, presenting with high illness acuity and high frailty were independent predictors of death
and a dose–response association between frailty and mortality was observed (CFS 1–4: reference;
CFS 5–6: HR 1.78, 95% CI 0.90, 3.53; CFS 7–8: HR 2.57, 95% CI 1.26, 5.24). Conclusions: Clinicians
should have a low threshold for testing for COVID-19 in older and frail patients during periods of
community viral transmission, and diagnosis should prompt early advanced care planning.
Keywords: atypical presentation; COVID-19; frailty; mortality; older patients
1. Introduction
In December 2019, doctors in China described a cluster of viral pneumonia cases
secondary to a novel Coronavirus named severe acute respiratory syndrome coronavirus
2 (SARS-CoV-2) [1]. The World Health Organization named this emergent disease coron-
avirus disease 19, or “COVID-19”, and declared a pandemic on 11 March 2020 [2]. One
of the main challenges of COVID-19 is the wide spectrum of clinical presentations, rang-
ing from asymptomatic cases to mild upper-respiratory-tract illness with myalgia and
fatigue [3,4], severe viral pneumonia [1,3–5], gastrointestinal symptoms [5,6], neurological
symptoms [7,8], cardiovascular symptoms [9,10] and other symptoms such as loss of smell
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and taste [11,12]. Atypical presentations [5] such as delirium [13,14], drowsiness [15],
syncope [16] and fall [17] have also been described in older patients (aged ≥ 65 years),
and our experience with other respiratory viral illnesses is that they often present without
the typical fever and respiratory features [18,19]. Indeed, many illnesses in older adults
present atypically in the form of a Geriatric Syndrome such as delirium, falls or reduced
physical functional ability [20,21]. Understanding the spectrum of disease presentation is
particularly important in COVID-19, given the necessity for prompt isolation of cases in
order to prevent nosocomial spread and unnecessary exposure of health and social care
staff.
Older adults are especially vulnerable to COVID-19 and experience high morbidity
and mortality as a result of infection [22]. Age is independently linked with mortality [22,23],
but age alone does not adequately capture the robustness of older adults who are a het-
erogeneous group. Some live well into old age and do not experience the “slowing up”
and vulnerabilities associated with the onset of frailty whilst others do [24,25]. Age alone
is also not adequate to determine the likely effectiveness of treatment options and assess
prognosis, as well as to make decisions regarding healthcare resource allocation [26].
Over the past few decades, there has been an explosion of research into frailty and its
operationalisation in the clinical setting. Assessment of frailty in older adults is now an
important part of Comprehensive Geriatric Assessment and it is necessary to understand
the relationships between frailty and both the clinical presentations and outcomes of
COVID-19. One study in patients over 80 years old showed mortality from COVID-19
was significantly higher in patients with frailty [23], another showed frailty was weakly
associated with higher risk of mortality [27] while a third study found that frailty is not a
good discriminator of prognosis in COVID-19 [28].
In this retrospective observational study, we aim to describe the range of clinical
presentations of older patients (≥65 years) admitted as an emergency to a University
Hospital and diagnosed with COVID-19. Information retrieved from our electronic health
record system will provide a detailed description of the presenting symptoms, radiological
findings and laboratory characteristics of this patient group, as a whole and by frailty status.
We will also describe the clinical trajectory of patients from admission to discharge in terms
of delirium, functional status and hospital outcomes, particularly exploring associations
between frailty and mortality in this cohort. This will add to our understanding of how
this emergent infectious disease affects older adults.
2. Materials and Methods
2.1. Study Design and Setting
This is a retrospective observational study conducted in a tertiary National Health
Service (NHS) University Hospital in England.
2.2. Sample
Any older adult (≥65 years old) admitted as an emergency from 1 March 2020 to
15 May 2020 and diagnosed with COVID-19 infection was included. Diagnosis was con-
firmed either by clinical suspicion of probable COVID-19 infection and/or positive viral
Polymerase Chain Reaction (PCR) for SARS-COV-2 viral RNA on nasopharyngeal swab.
2.3. Patient Characteristics
The following information was retrieved by the clinical informatics team from the
Electronic Health Record (EHR): age, sex, ethnicity, body mass index (BMI, Kg/m2), Clin-
ical Frailty Scale (CFS) score [25], number of ward moves (excluding the Emergency
Department or equivalent acute assessment area), PCR for SARS-COV-2 viral RNA results
and laboratory blood tests on admission. Laboratory values included C-reactive protein
(CRP; mg/L), total white blood cell (WBC), lymphocyte and neutrophil counts (109/L),
interleukin-6 (IL-6; pg/mL), creatinine (µmol/L), high sensitivity troponin I (HsTNI; ng/L)
and D-dimer (ng/mL). The maximum National Early Warning Score 2 (NEWS2) [29] and
Geriatrics 2021, 6, 11 3 of 13
associated vital signs (heart rate, systolic blood pressure, respiratory rate and temperature)
recorded in the first 4 h of admission were also retrieved. The CFS is a 9-point measure
of the overall level of fitness or frailty of an older adult. It is based on clinical judgement
of the patient’s status two weeks before the onset of the acute illness leading to hospital
admission. Higher scores indicate increasing frailty. The NEWS2 is an aggregate score
based on the deviation of bedside vital signs from a normal physiological range. Higher
scores indicate higher illness acuity.
Further clinical information was manually extracted from the EHR using a standard-
ised data collection tool. Presenting symptoms (history of fever, cough, breathlessness,
fatigue, myalgia, new or worsening confusion, fall, nausea and/or vomiting, diarrhoea,
abdominal pain, loss of taste and/or smell, or nonspecific illness), number of regular ad-
mission medications, multimorbidity (<2, 2 or >2 long term conditions), known dementia,
admission from a care home (residential versus dual registered/nursing homes), functional
status on admission and discharge (independently mobile, mobile using a stick, mobile
using a frame or immobile), admission chest X-ray (CXR) report [30] and evidence of
hospital-acquired disease (defined as diagnosis of COVID-19 infection >14 days after hos-
pital admission or if this was the diagnosis recorded by the treating team). Finally, whether
the patient developed new or worsening confusion or was diagnosed with delirium during
the admission episode was documented, after searching the EHR using the terms “confu-
sion” and “delirium”. Patients were also assigned a CFS score by the researcher if this had
not been recorded by the treating team in the EHR (102 (48%) patients). All CFS scores were
completed using information recorded in the EHR on the patient’s admission to hospital
and verified by a consultant or specialist registrar in Geriatric Medicine, experienced in the
assessment of frailty using the CFS. CFS scores derived from manual review of inpatient
records show good agreement with scores assigned after face to face assessment, with an
estimated Kappa of 0.84 for inter-rater reliability [31]. All CFS scores were assigned as soon
as possible after admission but it was not possible to blind researchers to the outcome if
patients had already died, as users are automatically notified of this when the electronic
patient record is accessed. Patients assigned a CFS score by the research team were younger
than other patients (median (interquartile range) ages: 76 years, (71,83) versus 84 years,
(77,89); p < 0.001) but there was no significant difference in sex (% women: 39.1% versus
47.3%, p = 0.27). The age difference reflects a policy at our centre, predating the pandemic,
which only mandates frailty scoring for patients aged 75 years and over. Therefore, many
patients aged 65–74 years old included in our cohort did not have a CFS score assigned by
their treating team.
For patients identified with hospital-acquired COVID-19 disease, laboratory test
results nearest to the first positive PCR for SARS-COV-2 viral RNA (within 12 h), the
maximum NEWS2 score, vital signs nearest to the first positive PCR for SARS-COV-2
viral RNA (within 4 h) and presenting features prompting the treating team to consider
a diagnosis of COVID-19 (including nearest CXR report) were used instead of results
at hospital admission. All laboratory tests and vital signs were extracted by the clinical
informatics team and presenting features were manually extracted from the EHR by the
research team.
2.4. Patient Outcomes
Death during the inpatient stay or within 14 days of discharge was the primary
outcome and was calculated using the dates of admission, discharge and death. The
maximum follow-up time was 45 days for each patient, either 45 days from the date of
admission or from the first positive swab in the case of hospital-acquired disease. It was
important to include deaths in the two weeks following discharge, since local preparations
for the COVID-19 pandemic included facilitation of early discharge to community palliative
care settings.
Other hospital outcomes reported were prolonged length of stay (LOS; defined as
a stay of ≥10 days), delayed discharge (defined as a stay >24 h after the last recorded
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“clinically fit date”, the date set by the treating team indicating fitness to leave hospital),
30-day readmission and new institutionalization (defined as a new admission to a care
home). All hospital and out-of-hospital outcomes were provided by the clinical informatics
team and available from the EHR.
2.5. Statistical Analysis
Descriptive characteristics were expressed as medians (interquartile range, IQR) and
percentages (frequency, % (n)). The characteristics of the cohort were described as a whole
and by frailty status. Frail (CFS ≥ 5) and nonfrail (CFS ≤ 4) patients were compared
using Kruskal Wallis and Chi squared tests, and Venn diagrams were used to illustrate key
differences. Cox proportional hazards regression further explored associations between
frailty and mortality. Frailty was categorised as: CFS 1–4 “Nonfrail”, CFS 5–6 “Mild to
Moderate Frailty” and CFS 7–8 “Severe to Very Severe Frailty”. Kaplan–Meier curves were
explored to ensure that there was no violation of the proportional hazards assumption.
Univariable and multivariable associations were explored after adjustment for age, sex,
illness acuity and multimorbidity (defined as the coexistence of 2 or more long-term
conditions). All analyses were performed using STATA (version 12).
3. Results
3.1. Patient Characteristics
There were 215 older inpatients eligible for this study and only 1 patient, who was
terminally ill prior to developing COVID-19 and died on arrival to hospital, was excluded.
A total of 213 (99.5%) patients had a PCR confirmed diagnosis while only 1 patient had
a clinical diagnosis of COVID-19. Mean age was 80.3 years (range 65 to 103), 94 (43%)
patients were women and 178 (83.2%) patients were White (Black: 1 [0.5%], Asian: 3 [1.4%];
other: 1 [0.5%], missing ethnicity or not stated: 31 [14.5%]). Table 1 further details the
characteristics of the cohort by level of frailty.
Table 1. Characteristics of the whole cohort and by frailty (CFS 1–4 “Nonfrail” versus CFS 5–8 “Frail”).




(n = 142) p
Age, years 80 (75, 87) 75 (70, 77) 84 (77, 89) <0.001
Sex, % (n) women 43.9 (94) 29.2 (21) 51.4 (73) 0.002
CFS 6 (4, 7) 3 (2, 4) 6 (6, 7) <0.001
BMI, Kg/m2 24.6 (21.2, 29.2) 26.5 (23.3, 31.2) 23.5 (20.1, 27.7) 0.0015
Known Dementia, % (n) 27.1 (58) 1.4 (1) 40.1 (57) <0.001
Admission from care home, % (n) 31.3 (67) 0 (0) 47.3 (67) <0.001
Pre-admission mobility, % (n)
<0.001
Independent 39.3 (84) 84.7 (61) 16.2 (23)
Stick 15.0 (32) 9.7 (7) 17.6 (25)
Frame 33.6 (72) 5.6 (4) 47.9 (68)
Immobile 12.2 (26) 0 (0) 18.3 (26)
Symptoms, % (n)
Fever 73.4 (157) 81.9 (59) 69.0 (98) 0.043
Cough 63.6 (136) 76.4 (55) 57.0 (81) 0.005
SOB 59.8 (128) 62.5 (45) 58.5 (83) 0.568
Fatigue 48.1 (103) 62.5 (45) 40.8 (58) 0.003
Myalgia 14.5(31) 26.4 (19) 8.5 (12) <0.001
Confusion 36.9 (79) 20.8 (15) 45.1 (64) 0.001
Fall 20.6 (44) 12.5 (9) 24.7 (35) 0.038
N & V 18.7 (40) 25.0 (18) 15.5 (22) 0.092
Diarrhoea 16.4 (35) 31.9 (23) 8.5 (12) <0.001
Abdominal pain 7.0 (15) 12.5 (9) 4.2 (6) 0.025
Taste/ smell 4.7 (10) 9.7 (7) 2.1 (3) 0.013
Non-specifically unwell 19.2 (41) 6.9 (5) 25.4 (36) 0.001
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(n = 142) p
Multimorbidity, % (n)
<0.001
<2 LTC 7.5 (16) 16.7 (12) 2.8 (4)
2 LTC 9.8 (21) 16.7 (12) 6.3 (9)
≥3 LTC 82.7 (177) 66.7 (48) 90.8 (129)
Polypharmacy, % (n)
<0.0010–4 medications 21.0 (45) 36.1 (26) 13.4 (19)5–9 medications 51.9 (111) 45.8 (33) 54.9 (78)
≥10 medications 27.1 (58) 18.1 (13) 31.7 (45)
CXR on COVID-19 presentation % (n)
Classical/Probable COVID-19 34.6 (74) 50.0 (36) 26.8 (38)
Indeterminate for COVID-19 17.8 (38) 19.4 (14) 16.9 (24)
Non COVID-19 Features 18.7 (40) 9.7 (7) 23.2 (33)
Normal 28.5 (61) 20.8 (15) 32.3 (46) 0.002
Hospital Acquired Disease, % (n) 9.8 (21) 11.1 (8) 9.2 (13) 0.649
Time to first positive swab *, days 0 (0, 1) 0 (0, 1) 0 (0, 1) 0.290
Acuity, % (n) yes
Low (NEWS2 <5) 45.3 (97) 50.0 (36) 43.0 (61)
High (NEWS2 ≥5) 54.7 (117) 50.0 (36) 57.0 (81) 0.328
Vital signs, % (n)
Fever >38.0 ◦C 28.5 (61) 40.3 (29) 22.5 (32) 0.007
Respiratory rate >24 bpm 38.8 (83) 36.1 (26) 40.1 (57) 0.568
Systolic blood pressure ≤90 mmHg 3.3 (7) 0 (0) 4.9 (7) 0.060
Pulse >130 bpm 5.1 (11) 5.6 (4) 4.9 (7) 0.845
Laboratory Values
White blood cells, 109/L 6.9 (5.0, 9.6) 6.3 (4.9, 8.6) 7.4 (5.1, 10.0) 0.094
Neutrophils, 109/L 5.4 (3.7, 7.8) 4.8 (3.6, 7.2) 5.8 (3.8, 8.2) 0.19
Lymphocytes, 109/L
0.67 0.61 0.67
0.28(0.48, 1.01) (0.46, 0.90) (0.50, 1.04)
Creatinine, µmol/l
89.0 87.5 89.5
0.32(71.1, 118.5) (69.5, 111.0) (71.6, 128.6)
C-Reactive Protein, % (n)
0.007
<40 mg/L 30.3 (65) 18.1 (13) 36.7 (52)
40–100 mg/L 31.3 (67) 30.6 (22) 31.7 (45)
>100 mg/L 37.4 (80) 50.0 (36) 31.0 (44)










D Dimer, % (n)
≤230 ng/mL 15.6 (35) 16.7 (12) 16.2 (23)
>230 ng/mL 54.2 (116) 54.1 (39) 54.2 (77) 0.942
* excluding 8 patients who were swabbed in the community and 1 patient who never had a positive swab; IQR: Interquartile range; CFS:
Clinical Frailty Scale; Non-rail = CFS 1–4 and Frail = CFS 5–8; BMI: body mass index (available for 63 nonfrail and 130 frail patients); LTC:
Long-term condition(s); CXR: Chest X-ray; Interleukin-6 (available for 42 non-rail and 85 frail patients). Percentages may not add up to
100% due to missing data.
3.2. Relationship between Clinical Characteristics and Frailty
Frail patients were significantly older and more likely to be women with lower BMI.
They were also more likely to have dementia, multimorbidity and polypharmacy, and to
be admitted from a care home. In terms of presenting symptoms, frail patients were less
likely to complain of fever, cough, myalgia, fatigue, gastrointestinal symptoms or loss of
taste and smell on presentation than nonfrail patients, but were more likely to have new
or worsening confusion, an acute fall, or nonspecific illness as part of their presenting
features. These latter three features are common acute geriatric illness presentations, and
the differences in their prevalence between frail and nonfrail patients is striking (Figure 1).
Geriatrics 2021, 6, 11 6 of 13
Geriatrics 2021, 6, x FOR PEER REVIEW 6 of 13 
 
 
nonfrail and 130 frail patients); LTC: Long-term condition(s); CXR: Chest X-ray; Interleukin-6 (available for 42 non-rail 
and 85 frail patients). Percentages may not add up to 100% due to missing data. 
3.2. Relationship between Clinical Characteristics and Frailty 
Frail patients were significantly older and more likely to be women with lower BMI. 
They were also more likely to have dementia, multimorbidity and polypharmacy, and to 
be admitted from a care home. In terms of presenting symptoms, frail patients were less 
likely to complain of fever, cough, myalgia, fatigue, gastrointestinal symptoms or loss of 
taste and smell on presentation than nonfrail patients, but were more likely to have new 
or worsening confusion, an acute fall, or nonspecific illness as part of their presenting 
features. These latter three features are common acute geriatric illness presentations, and 
the differences in their prevalence between frail and nonfrail patients is striking (Figure 
1). 
 
Figure 1. Venn Diagrams illustrating the prevalence of common geriatric illness by frailty with COVID-19 infection. Non-
frail: Clinical Frailty Score 1–4; Frail: Clinical Frailty Score 5–8; NOS: Nonspecific illness. 
There was no difference between frail and nonfrail patients in terms of their illness 
acuity on presentation of COVID-19 infection. Laboratory markers were also similar, with 
the exception of CRP and IL-6, which were higher in nonfrail patients (Table 1), and 
HsTNI, which was higher in frail patients. In terms of radiologic features, frail patients 
were more likely to have a normal CXR at the time of COVID-19 presentation compared 
to nonfrail patients. Similar proportions of frail and nonfrail patients acquired COVID-19 
in hospital (Table 1). 
3.3. Relationship between Inpatient Trajectory and Frailty 
In terms of inpatient trajectory, frail patients were much less likely to be cared for in 
a high-care ward than nonfrail older adults but were much more likely to experience de-
lirium (Table 2). There were 57.0% of frail patients who experienced new or worsening 
confusion, or received a diagnosis of delirium, during the admission episode compared 
to 29.2% of nonfrail patients. Frail patients were also more likely to be immobile on dis-
charge and experience delayed discharge, remaining in hospital after their clinically fit 
date. There were also nonsignificant trends for longer lengths of inpatient stay, higher 30-
day readmission and new institutionalisation amongst frail patients compared to nonfrail 
patients (Table 2). 
Figure 1. Venn Diagrams illustrating the prevalence of common geriatric illness by frailty with COVID-19 infection. Nonfrail:
Clinical Frailty Score 1–4; Frail: Clinical Frailty Score 5–8; NOS: Nonspecific illness.
There was no difference between frail and nonfrail patients in terms of their illness
acuity on presentation of COVID-19 infection. Laboratory markers were also similar, with
the exception of CRP and IL-6, which were higher in nonfrail patients (Table 1), and HsTNI,
which was higher in frail patients. In terms of radiologic features, frail patients were more
likely to have a normal CXR at the time of COVID-19 presentation compared to nonfrail
patients. Similar proportions of frail and nonfrail patients acquired COVID-19 in hospital
(Table 1).
3.3. Relationship between Inpatient Trajectory and Frailty
In terms of inpatient trajectory, frail patients were much less likely to be cared for
in a high-care ward tha nonfrail older adults but were much more likely to experience
delirium (Table 2). There were 57.0% of frail patients who experi nced new or worsening
confusion, or receiv d a diagnosis of delirium, during th admission episode compared
t 29.2% of nonfrail patients. Frail patients were also more likely to be immobile on
discharge and experience delayed discharge, remaining in hospital after their clinically fit
date. There were also nonsignificant trends for longer lengths of inpatient stay, higher 30-
day readmission and new institutionalisation amongst frail patients compared to nonfrail
patients (Table 2).
Table 2. Hospital Trajectory and Outcome of the whole cohort and by frailty (CFS 1–4 “Nonfrail” versus CFS 5–8 “Frail”).




(n = 142) p
Ward moves, % (n)
0.021
Up to 1 42.1 (90) 44.4 (32) 40.8 (58)
2 33.2 (71) 27.8 (20) 35.9 (51)
3 15.4 (33) 12.5 (9) 16.9 (24)
4 or more 9.4 (20) 14.3 (11) 6.4 (9)
Admission to High Care, % (n) 10.3 (22) 29.2 (21) 0.7 (1) <0.001
Delirium or new confusion during admission at any point, % (n) 47.7 (102) 29.2 (21) 57.0 (81) <0.001
Mobility at discharge *, % (n)
<0.001
Independent 35.0 (49) 75.4 (43) 7.2 (6)
Stick 5.7 (8) 3.5 (2) 7.2 (6)
Frame 37.1 (52) 17.5 (10) 50.6 (42)
Immobile 20.0 (28) 0 (0) 33.7 (28)
Length of stay, days # 11 (6, 18) 8 (4, 17) 12 (7, 19) 0.08
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(n = 142) p
Hospital outcomes, % (n)
Inpatient Death 34.6 (74) 20.8 (15) 41.6 (59) 0.003
Death as inpatient or within 14 days of discharge 38.3 (82) 22.2 (16) 46.7 (66) 0.001
Prolonged length of stay (>10 days) 53.5 (114) 45.1 (32) 57.8 (82) 0.08
New Institutionalisation * 5.6 (12) 3.5 (2) 12.1 (10) 0.08
Readmission * 19.3 (27) 15.8 (9) 21.7 (18) 0.385
Delayed transfer of care * 46.4 (65) 26.3 (15) 60.2 (50) <0.001
# values presented as median with interquartile range; * n = 140 (those who died excluded); CFS: Clinical Frailty Scale; Nonfrail = CFS 1–4
and Frail= CFS 5–8. Percentages may not add up to 100% due to missing data.
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Age, years 1.04 1.02, 1.07 1.04 1.01, 1.07 
Sex     
Women Ref  Ref  
Men 1.47 0.94, 2.30 2.03 1.27, 3.24 
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Multimorbidity     
0–1 LTC Ref  Ref  
Figure 2. Survival after presentation with COVID-19 infection by Clinical Frailty Scale (CFS) Score. * The time from
COVID-19 presentation is defined as the number of days from either admission to hospital or time from first positive swab
if hospital acquired disease. For those discharged alive, follow-up was extended for the first 14 days after discharge.
Associations between frailty and mortality were further explored using Cox (Pro-
portional Hazards) regression (Table 3). The dose–response association between higher
frailty and higher mortality persisted after adjustment for age, sex, illness acuity and
multimorbidity.
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Table 3. Cox Proportional Hazards Regression Analysis: relationships between age, sex, frailty, illness acuity, multimorbidity
and death.
Univariable Analysis Multivariable Analysis
Characteristic HR 95% ConfidenceInterval HR
95% Confidence
Interval
Age, years 1.04 1.02, 1.07 1.04 1.01, 1.07
Sex
Women Ref Ref
Men 1.47 0.94, 2.30 2.03 1.27, 3.24
CFS
1–4 Ref Ref
5–6 1.99 1.11, 3.59 1.78 0.90, 3.53
7–8 2.83 1.54, 5.19 2.57 1.26, 5.24
Acuity, NEWS2
Low (<5) Ref Ref
High (≥5) 2.30 1.42, 3.65 2.33 1.45, 3.74
Multimorbidity
0–1 LTC Ref Ref
2 LTC 0.99 0.30, 3.28 0.89 0.22, 2.68
≥3 LTC 1.44 0.58, 3.58 0.85 0.32, 2.30
HR: Hazard Ratio; CFS: Clinical Frailty Scale; NEWS2: National Early Warning Score 2; LTC: long term condition(s). HRs adjusted for all
co-variables in multivariable models.
4. Discussion
We have described the clinical features and inpatient trajectory of older inpatients
with clinically confirmed COVID-19 admitted as an emergency to an NHS University
Hospital in England. Our findings confirm the range of symptoms other than fever, cough
and breathlessness that are common presenting features of COVID-19 infection in this
population group. Furthermore, we found frail patients were more likely to present with
new or worsening confusion, falls and nonspecific illness and less likely to present with
fever and cough than nonfrail older adults. This is in keeping with other studies [14,32]
and characterises the “typical atypical” way in which older patients, particularly those
living with frailty, often present with acute illness.
New or worsening confusion was present in 36.9% of all patients on admission and
57.0% of frail patients experienced new or worsening confusion at some point during their
admission episode, either formally diagnosed as delirium or noted as a symptom by their
healthcare team. High prevalence of delirium associated with COVID-19 infection has been
identified in other studies [28], yet local and national guidelines often fail to emphasise
the importance of delirium as a potential indicator of COVID-19 illness [33]. Therefore,
our findings on the prevalence of delirium and the range of other presenting features of
COVID-19 in hospitalized older adults support low thresholds for COVID-19 testing in
this population group [5] during periods of significant community viral transmission.
Overall, in-hospital mortality was 34.6%, which reflects the severity of the disease and
the older age of our population and is similar to other studies [22,23]. Frail patients were
more likely to die than nonfrail patients, and a dose–response relationship was observed,
which persisted after adjustment for age, sex, illness acuity and multimorbidity. This
finding supports measurement of frailty in this patient group to aid identification of older
adults most vulnerable to this disease. Early identification of patients likely to have a
complex clinical course allows for early advanced care planning, involving the patient
and their families in treatment decisions, and patients can be prioritized for interventions
known to improve outcomes in older hospitalized adults; for example, comprehensive
geriatric assessment delivered by multidisciplinary teams on specialist medicine for the
elderly wards [34]. However, frailty has not been consistently associated with mortality
across all reports, with some supporting our findings [22,35], another equivocal [27] and one
reporting no association [28]. Differing results to date may reflect small sample sizes and
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it is likely that large multicentre studies or meta-analyses will be required. Interestingly,
results from the COPE study, which includes over 1500 patients with COVID-19 from
several centres across the United Kingdom and Italy, support an association between
higher frailty and higher mortality from COVID-19 [35].
There is considerable interest in understanding the pathogenesis of COVID-19 and
pathways to mortality. We observed that 28.5% of our patient cohort had a normal CXR
around the time of COVID-19 presentation and only 34.6% had classic or probable CXR fea-
tures suggestive of the disease. This is similar to a study in 64 younger patients (mean age
of 56 years) [36] and reinforces the message that a negative result does not exclude COVID-
19 illness [30,37]. We also note that this observation was exaggerated in frail patients, with
only 1 in 4 patients having classical or probable CXR changes on presentation compared
to 1 in 2 older adults without frailty. This could reflect the underlying vulnerability of
frail patients, who may be less able to compensate for the effects of COVID-19 illness and
present before the radiological features of lung inflammation have developed. However, it
could also indicate that the manifestations of the illness differ by level of frailty.
Other reports have suggested that there may be differences in the physiological
response to COVID-19 infection by frailty status. For example, another cohort study
found inflammatory responses blunted in frail compared to nonfrail patients [28]. This
is consistent with our findings in relation to CRP and IL-6, which were significantly
higher in nonfrail patients. It is possible that frail older adults are not able to mount
strong immune responses to COVID-19 infection due to immunosenescence [38]. Higher
inflammatory responses to COVID-19 have been associated with poorer outcomes [39],
and dexamethasone, an immunosuppressant therapy, reduced mortality in patients with
COVID-19 requiring oxygen therapy or mechanical ventilation [40]. Therefore, if immune
responses differ between frail and nonfrail patients, this may have implications for the
likely effectiveness of different treatments, and trials examining potential therapies should
include measurement of frailty in older adults. It is also possible, as with the differences in
CXR features, that frail patients are presenting earlier in their illness trajectory and hence
have lower levels of inflammatory markers on presentation. However, we also found
that higher proportions of frail compared to nonfrail older patients presented with raised
HsTNI levels, and there was a nonsignificant trend for higher neutrophil count. These
findings hint at potential alternative pathological consequences of COVID-19 infection in
older adults with frailty, with cardiac complications and bacterial superinfection perhaps
more likely eventual causes of death than high levels of systemic inflammation.
Our data did not confirm a difference in the LOS between frail and nonfrail patients,
unlike other studies [35], although there was a trend in this direction and frail patients
were more likely to stay in hospital beyond their clinically fit date. Delayed transfer of care
has been previously observed in association with frailty and likely reflects difficulties in
sourcing social care or onward care facilities, such as inpatient rehabilitation centres and
care homes [41]. Consistent with this, frail patients had lower mobility on discharge than
nonfrail patients.
Nonfrail patients were more likely to be admitted to the intensive care wards compared
to frail patients (29% vs. 0.7%, p < 0.001). This suggests that in our centre, decisions
regarding admissions to critical care were considered appropriately in our cohort in keeping
with clinical guidelines [42]. It should be noted, however, that decisions on access to critical
care or mechanical ventilation for older adults should remain individualized and take into
consideration patients’ preference and goals of care [26]. Such decisions are not based
on any one factor but a holistic patient assessment, weighing up the risks and benefits of
intensive care treatment.
Our study has some limitations. It is a single-centre study, and our results are not
generalisable to the whole population. For example, the older population in our local
area is a highly homogenous demographic consisting mostly of individuals of White
ethnicity. The impact of ethnicity on the morbidity and mortality of this disease has been
widely reported [43,44] but we were not able to add to this. The sample size was also
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relatively small after accounting for inpatient mortality, thus limiting the potential to
detect differences between frail and nonfrail patients with respect to secondary outcome
measures. Additionally, only routinely collected data were available and some patients
were not assessed by their treating team for frailty, necessitating scoring by the research
team who may have been aware of the outcome in some cases. However, scoring was
done by physicians experienced in frailty assessment at our centre and based only on
information documented in the EHR on the patient’s admission to hospital, a validated
method [31]. Finally, more detailed information regarding Intensive Care Unit (ICU)
admission, treatments and mechanical ventilation was not included, as this is currently
being evaluated in a larger study at our institution.
The absence of CFS in some of our patients, necessitating scoring by the research
team, was partly due to the inclusion of patients ≥65 years old, whereas routine frailty
scoring in our centre is only mandated for patients aged ≥75 years. Thus, the median age
of those patients scored by the research team was younger than patients assigned scores by
their treating team. However, it may also suggest the unfamiliarity of some clinicians with
this scoring system, though widespread. As a result of changes to workforce organisation
in preparation for the pandemic, many clinicians who were not familiar with modern
geriatric medicine practices were incorporated into acute and general medicine rotas and
older people’s therapy teams were temporarily redeployed. This may have contributed
to lower-than-expected assessment of frailty by treating teams and supports the need for
local educational and quality improvement work to increase awareness of frailty, its clinical
assessment and association with patient outcomes [26,41].
The main strengths of our study are that it offers a detailed description of the clinical
presentation, laboratory profile and inpatient trajectory of a cohort of hospitalised older
adults with COVID-19 and includes a description of these patients by level of frailty. Data
were retrieved digitally from the EHR or manually using a standardised data collection
tool and missing data were limited. Also, the use of an EHR system in our hospital enabled
clinicians to review patient medical records remotely, without the need for research staff to
enter clinical areas and increase the risk of infection.
5. Conclusions
Older adult inpatients with COVID-19 infection are likely to present with atypical
symptoms, develop delirium and have a high mortality, especially if they are also living
with frailty. Clinicians should have a low threshold for testing for COVID-19 in older and
frail patients when there is community transmission of COVID-19, and diagnosis should
prompt early advanced care-planning discussions.
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